36,624 Results

Draft NICE guidance does not recommend Onpattro for hereditary transthyretin-related amyliodsis.- Alnylam Pharmaceuticals.

 Added 1 day ago

The National Institute for Health and Care Excellence has issued draft guidelines rejecting NHS funding for Onpattro (patisiran), from Alnylam...

Duke Clinical Research Institute is leading a new clinical study,COORDINATE-Diabetes trial, to optimize care for people with type 2 diabetes and cardiovascular disease . Eli Lilly + Boehringer.

 Added 1 day ago

The Duke Clinical Research Institute (DCRI) is leading a new clinical study to optimize care for people with type 2...

Draft guidance from NICE rejects the use of Tegsedi in hereditary transthyretin-related amyliodsis.- Akcea Therapeutics.

 Added 1 day ago

The National Institute for Health and Care Excellence has issued draft guidelines rejecting NHS funding for Tegsedi (inotersen), from Akcea...

Bausch Health Companies Inc., acquires asets of Synergy Pharma including Trulance to treat chronic idiopathic constipation and IBS.

 Added 1 day ago

Bausch Health Companies Inc. announced that it has entered into a definitive agreement to acquire certain assets of Synergy Pharmaceuticals...

European Commission approval for self-administration of Xolair across all indications.- Novartis

 Added 1 day ago

Novartis announced that the European Commission (EC) has approved Xolair (omalizumab) prefilled syringe (PFS) for self-administration, allowing patients with severe...

Phase III ECLIPSE study of Tremfya demonstrates superiority to Cosentyx in plaque psoriasis.- Janssen.

 Added 2 days ago

The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from the ECLIPSE study demonstrating that Tremfya (guselkumab) was superior...

FDA approves Tolsura for fungal infections.- Mayne Pharma.

 Added 2 days ago

Mayne Pharma Group announced that the FDA has approved the New Drug Application (NDA) for Tolsura (SUBA-itraconazole) 65mg capsules. Tolsura...

Rafael Pharmaceuticals, initiates a phase III trial of CPI 613 to treat metastatic adenocarcinoma of the pancreas.

 Added 2 days ago

Rafael Pharmaceuticals, Inc. announced the initiation of a phase III multicenter, open-label, randomized pivotal trial (AVENGER 500) to evaluate the...

FDA accepts for review NDA for lumateperone to treat schizophrenia.-Intra-Cellular Therapies

 Added 2 days ago

Intra-Cellular Therapies announced that the FDA has accepted for review its New Drug Application (NDA) for lumateperone, an investigational agent...

Retrospective analysis shows significant reductions in postsurgical pain and opioid requirements with Exparel in Cesarean Section patients.- Pacira Pharma

 Added 2 days ago

Pacira Pharmaceuticals, Inc. announced the publication of new data from a retrospective investigator-initiated study analyzing the use of Exarel (bupivacaine...

Load more